US 11,912,740 B2
Honey proteomics for honeybee disease and environmental biomonitoring
Rocio Solange Cornero, Arlington, VA (US); Alessandra Luchini Kunkel, Burke, VA (US); Lance A. Liotta, Fairfax, VA (US); and Claudius Mueller, Warrenton, VA (US)
Assigned to GEORGE MASON RESEARCH FOUNDATION, INC., Fairfax, VA (US)
Filed by George Mason University, Fairfax, VA (US)
Filed on Dec. 9, 2020, as Appl. No. 17/115,988.
Claims priority of provisional application 62/955,618, filed on Dec. 31, 2019.
Prior Publication US 2021/0198308 A1, Jul. 1, 2021
Int. Cl. C07K 1/22 (2006.01); G01N 33/58 (2006.01); G01N 33/68 (2006.01); B01J 20/28 (2006.01); B01J 20/26 (2006.01); B01J 20/285 (2006.01)
CPC C07K 1/22 (2013.01) [B01J 20/261 (2013.01); B01J 20/262 (2013.01); B01J 20/285 (2013.01); B01J 20/28016 (2013.01); B01J 20/28023 (2013.01); G01N 33/587 (2013.01); G01N 33/6848 (2013.01); G01N 2800/50 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A method of assessing the risk of colony collapse disorder (CCD) in a bee hive, comprising:
contacting a honey sample obtained from the bee hive with a substrate functionalized with one or more reactive dyes;
recovering proteins associated with the substrate;
determining an amino acid sequence of the proteins; and
determining that the bee hive is at an increased risk for CCD when the amino acid sequence is from a bee pathogen or a bee stress biomarker, or
determining that the bee hive is not at an increased risk for CCD when the amino acid sequence is not from a bee pathogen or a bee stress biomarker.